NCT07090031进行中（未招募）2 期
Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer: A Single-arm, One Center Study
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- pCR
研究概览
简要总结
5-Fluorouracil (5-FU) based chemoradiotherapy is regarded a standard perioperative treatment in locally advanced rectal cancer, but the effective rate still low. We investigate oral TAS-102 plus oxaliplatin concurrent radiotherapy for stage II or III local advanced rectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible patients are 18 years or older and have histologically confirmed adenocarcinoma of the rectum (defined as the distal border of the tumour less than 16 cm from the anal verge measured by rigid rectoscopy) with no evidence of distant metastases (identified by abdominal ultrasound or CT scan and chest radiography).
- •Patients in the adjuvant cohort have undergone R0-resection by total mesorectal excision (TME) of a pT3-4 N any or T any N positive non-metastatic rectal cancer.
- •Patients treated in the neoadjuvant cohort need to have a clinical T3-4 N any or T any N positive tumour staged by endoscopic ultrasound, provided the lower border of the tumour is located 0 - 16 cm from the anal verge measured by rigid rectoscopy and the primary tumour is deemed resectable by TME surgery on the basis of clinical assessment. Other eligibility criteria comprise: WHO status of zero or one; adequate liver, renal, and bone marrow function defined as follows: leucocyte count > 3,500/µl, thrombocyte count > 100,000/µl, hemoglobin > 10.0 g/dl; serum bilirubin < 2.0 mg/dl, serum creatinine < 2.0 mg/dl.
排除标准
- •Prior treatment for rectal cancer, prior chemo- or immunotherapy, prior pelvic radiotherapy, or a history of other malignant diseases within the past five years with the exception of successfully treated basal carcinoma of the skin or carcinoma in situ of the uterine cervix.
- •Participation in another trial, pregnancy, breast-feeding, unwillingness to use effective contraception, or a medical condition or concomitant illness which could potentially interfere with compliance to the protocol are regarded as exclusion criteria, as well.
研究组 & 干预措施
TAS-102 in combination with oxaliplatin and concurrent radiotherapy
Experimental
干预措施: TAS-102 in combination with oxaliplatin (Drug)
结局指标
主要结局
pCR
时间窗: 24 monthss
pathalogical complete response rate
pathologiccal complete response rate
时间窗: 24 months
tumor cell complete disappear pathologiccally
次要结局
未报告次要终点
研究者
Youxin Ji
director
Qingdao Central Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal CancerEnvafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal CancerNCT06239870Yunnan Cancer Hospital35
Unknown
2 期
FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World StudyRectal CancerNCT02887313Sun Yat-sen University200
已完成
2 期
Perioperative mFOLFOX-6 in Locally Advanced Gastric CancerAdvanced Gastric CancerNCT02142322Seoul National University Hospital52
终止
2 期
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06Endometrial CancerGastrointestinal ComplicationsRadiation ToxicityUrinary ComplicationsNCT01164150Cancer Trials Ireland92
已完成
2 期
Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell CancerLocally Advanced Resectable Oral Cavity Squamous Cell CancerNCT01914900Fondazione IRCCS Istituto Nazionale dei Tumori, Milano14